India’s first Covid vaccine gets nod for human trials

Chennai: India’s ‘first’ indigenous COVID-19 vaccine COVAXIN, developed by Hyderabad-based Bharat Biotech in collaboration with ICMR and NIV, has got the nod for human clinical trials from the Drug Controller General of India.

According to the company, the Phase I and Phase II clinical trials of the vaccine for SARS-CoV-2, approved after pre-clinical studies demonstrated safety and immune response, would start across the country next month.

The collaboration with Indian Council of Medical Research (ICMR) and the National Institute of Virology (NIV) was instrumental in the development of the vaccine, it added.

The vaccine was developed and manufactured in Bharat Biotech’s facility at Genome Valley in Hyderabad, India.

 

NT Bureau